International Diabetes Federation. Diabetes Atlas, 2023. Accessed 27/06/2023. Available from: https://diabetesatlas.org/

Ong KL, Stafford LK, McLaughlin SA, et al; GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 2023;402:203-34. https://doi.org/10.1016/S0140-6736(23)01301-6

NHS Digital. National Diabetes Audit Core Report 1: Target 2021-22. 2023 [cited 2023 05/01/2022]; Available from: https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-audit/nda-core-21-22/nda-core-21-22-data.

Ahlqvist E, Storm P, Karajamaki A, et al. Novel subgroups of adult- onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol 2018; 6(5):361-9. https://doi.org/10.1016/S221308587(18)30051-2

Misra S, Wagner R, Ozkan B, et al. Systematic review of precision subclassification of type 2 diabetes. medRxiv https://doi.org/2023.04.19.23288577.

Dennis JM. Precision medicine in type 2 diabetes: using individualized prediction models to optimize selection of treatment. Diabetes 2020;69:2075-85. https://doi.org/10.2337/dbi20-0002

Dennis JM, Shields BM, Henley WE, et al. Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial data. Lancet Diabetes Endocrinol 2019;7(6):442-51. https://doi.org/10.1016/S2213-8587(19)30087-7

Malandrino N, Smith RJ. Personalized medicine in diabetes. Clinical Chemistry 2011;57(2):231-40. https://doi.org/10.1373/clinchem.2010.156901

National Institute for Health and Care Excellence. Type 2 diabetes in adults: management. NICE guideline 28 2015, updated 2022.

National institute for Health and Care Excellence. NG28 Patient Decision Aid on type 2 diabetes, 2022 [cited 2023 16/01/2023]; Available from: https://www.nice.org.uk/guidance/ng28/resources/patient-decision-aid-pdf-2187281198

Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2022;45(11):2753-86. https://doi.org/10.2337/dci22-0034

Anderson SL, Beutel TR, Trujillo JM. Oral semaglutide in type 2 diabetes. J Diabetes Complications 2020;34(4):107520. https://doi.org/10.1016/j.jdiacomp.2019.107520

Andreadis P, Karagiannis T, Malandris k, et al. Semaglutide for type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes, Obes Metab 2018;20(9):2255-63. https://doi.org/10.1111/dom.13361

Husain M, Bain SC, Holst AG, et al. Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials. Cardiovasc Diabetol 2020;19(1):156. https://doi.org/10.1186/s12933-01106-4

Husain M, Bain SC, Jeppesen OK, et al. Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk. Diabetes Obes Metab 2020;22(3):442-51. https://doi.org/10.1111/dom.13955

Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New Engl J Med 2016; 375(19):1834-44. https://doi.org/10.1056/NEJMoa1607141

Wang F, Mao Y, Wang H, et al. Semaglutide and diabetic retinopathy risk in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Clin Drug Investig 2022;42:17-28. https://doi.org/10.1007/s40261-021-01110-w

Health Research Authority. FOCUS – semaglutide effect on diabetic retinopathy, 2023. Accessed 04/07/2023. Available from: https://hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/focus-semaglutide-effect-on-diabetic-retinopathy/

Davies M, Pieber TR, Hartoft-Nielsen M-L, et al. Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial. JAMA 2017318(15):1460-70. https://doi.org/10.1001/jama.2017.14752

Lingvay I, Catarig A-M, Frias JP, et al. Efficacy and safety of once- weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol 2019; 7(11):834-44. https://doi.org/10.1016/S2213-8587(19)30311-0

Marzullo P, Daffara T, Mele C, et al. Real-world evaluation of weekly subcutaneous treatment with semaglutide in a cohort of Italian diabetic patients. J Endocrinol Invest 2022;45(8):1587-98. https://doi.org/10.1007/s40618-022-01799-2

Crabtree TSJ, Adamson K, Reid H, et al. Injectable semaglutide and reductions in HbA1c and weight in the real world in people switched from alternative glucagon-like peptide-1 receptor agonists. Diabetes Obes Metab 2022;24(7):1398-401. https://doi.org/10.1111/dom.14701

DeSouza C, Cariou B, Garg S, et al. Efficacy and safety of semaglutide for type 2 diabetes by race and ethnicity: a post hoc analysis of the SUSTAIN trials. The Journal of Clinical Endocrinology & Metabolism 2020;105(2):543-56. https://doi.org/10.1210/clinem/dgz072

Marshall A, Altman DG, Holder RL, et al. Combining estimates of interest in prognostic modelling studies after multiple imputation: current practice and guidelines. BMC Med Res Methodology 2009; 9:57. https://doi.org/10.1186/1471-2288-9-57

Health Research Authority. Confidentiality Advisory Group. 2021 [cited 2022 02/03/2022]. Available from: https://www.hra.nhs.uk/approvals-amendments/what-approvals-do-i-need/confidentiality-advisory-group/

Department of Health and Social Care, Medicines Supply Notification – MSN/2022/08 Semaglutide (Ozempic®) 1mg/0.74ml solution for injection 3ml pre-filled disposable device 2022: gov.uk